ARTICLE | Emerging Company Profile
Acceleron: Value in the wallflower
July 17, 2006 7:00 AM UTC
Acceleron Pharma Inc. is developing protein therapeutics that target the transforming growth factor beta superfamily to treat diseases ranging from musculoskeletal and metabolic disorders to cancer. Last month, Acceleron began Phase I testing of its lead candidate, ACE-011, a first-in-class activin receptor IIa antagonist to treat bone loss disorders.
President and CEO Glenn Batchelder said TGF beta bone growth factors represent "an under-appreciated space in biology that had not been exploited for its therapeutic potential."...